Analyst consensus rating
Sionna Therapeutics Analyst Rating: none
SION is rated none by 6 analysts with a $15.17 target. As of 2026-09-02.
Direct answer
Sionna Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.17.
Forecast evidence checked September 2, 2026.
Get free Sionna Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.90
- Average price target
- $15.17
- High price target
- $63.00
- Low price target
- $5.00
- Low target gap
- -27.5%
- Target upside
- +119.8%
- High target gap
- +813%
- Target range width
- 840.6%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sionna Therapeutics?
Sionna Therapeutics has a verified none consensus. The same dataset has an average price target of $15.17.
How far are Sionna Therapeutics's low and high targets from the recorded price?
The low target implies -27.5%, while the high target implies +813%.
How many analysts are included in Sionna Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Sionna Therapeutics's target upside or downside calculated?
The average target of $15.17 is divided by the recorded price of $6.90, then one is subtracted to produce +119.8%. This does not guarantee a future return.
When was Sionna Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.